检索结果-南通市图书馆

膳食补充剂(极爱胶囊^TM)改善患者胃肠道症状与生活质量的临床观察

International Journal of Clinical Medicine 2023年第5期

作者： Alex Spinoso Robert Settineri Christine Mclaren garth l.nicolson

来源：博看期刊评论

在线全文

博看期刊

学校读者我要写书评

暂无评论

中国烧伤创疡杂志 2020年第5期32卷 311-316页

作者： leigh E.Connealy Robert Settineri Ariel Causey Ashley Athanas Kathleen McCall-Smith Jason Clark Christine E.Mclaren garth l.nicolson 尔湾市新医学中心加利福尼亚州尔湾92618 尔湾市塞拉生产研究中心加利福尼亚州尔湾92612 加利福尼亚大学尔湾分校医学院统计部加利福尼亚州尔湾92697 亨廷顿海滩分子医学研究所分子病理学系加利福尼亚州亨廷顿海滩92648

目的通过一项开放标签研究明确一种含有植物成分和食用油的膳食补充剂(极爱胶囊^TM)是否可以减轻胃肠道不适患者主诉的胃肠道症状,从而改善其生活质量。方法纳入50例(女性40例,男性10例)患有胃肠道疾病或存在胃肠道症状的患者作为研究对... 详细信息

目的通过一项开放标签研究明确一种含有植物成分和食用油的膳食补充剂(极爱胶囊^TM)是否可以减轻胃肠道不适患者主诉的胃肠道症状,从而改善其生活质量。方法纳入50例(女性40例,男性10例)患有胃肠道疾病或存在胃肠道症状的患者作为研究对象,其平均年龄为(51.1±12.7)岁(年龄范围24~77岁),于每餐餐前30 min服用5粒膳食补充剂,连续服用90 d,研究期间采用功能性消化不良生存质量量表(functional digestive disorder quality of life questionnaire,FDDQl)与患者总体印象变化量表(patient global impression of change,PGIC)评估患者临床症状与生活质量。结果服用膳食补充剂后,患者综合评分显著提高(P=0.018),不适症状、日常活动和焦虑症状均显著改善(P=0.000、0.029、0.018),且多于服用膳食补充剂20 d内改善最明显,而饮食、睡眠、健康认知、疾病应对和压力影响均无明显改善(P=0.398、0.136、0.686、0.309、0.785);服用膳食补充剂90 d后,50例患者中有28例患者完成PGIC问卷调查评估,评分为(4.800±0.169)分,整体症状与生活质量均显著改善(P=0.000);研究期间,所有患者的血液抗氧化物、维生素、矿物质、必需脂肪酸、胰腺酶及氨基酸水平均未出现显著改变,安全性较高。结论极爱胶囊^(TM)可显著缓解肠易激综合征、胃食管反流等多种消化系统疾病患者的腹胀、腹痛等不适症状,改善患者日常活动状态及焦虑情绪等,提高患者生活质量,且安全性较高。

关键词：胃肠道症状生活质量膳食补充剂消化系统疾病植物成分食用油

针对转移大白鼠乳腺癌细胞表面抗原的单克隆抗体的特性鉴定

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

细胞与分子免疫学杂志 1986年第Z1期 27-27页

作者： Susan M.North garth l.nicolson 郭明 Department of Tumor Biology(108) U. T-M. D. Anderson Hospital and Tumor institufe 77030 Department of Tumor Biology(108) U. T-M. D. Anderson Hospital and Tumor institufe 77030

作者已获得一种针对13762NF大白鼠腺癌的转移克隆株(MTln3)所表达的细胞表面面抗原的单克隆抗体,这种McAb是用二种不同的免疫方案获得的。第一个方案是把一个携带同系肿瘤(MTln3)21天的供体脾细胞与小鼠骨髓瘤细胞的Y3 Ag,1、2、3相融... 详细信息

作者已获得一种针对13762NF大白鼠腺癌的转移克隆株(MTln3)所表达的细胞表面面抗原的单克隆抗体,这种McAb是用二种不同的免疫方案获得的。第一个方案是把一个携带同系肿瘤(MTln3)21天的供体脾细胞与小鼠骨髓瘤细胞的Y3 Ag,1、2、3相融合。用这一方法分离出许多产生抗体的克隆株。第二种方案采用的脾细胞来源于接受一种不完全提纯的粘蛋白样表面糖蛋白(gp580)反复免疫的小鼠,在13762NF小鼠中gp580的表达已被证

关键词：表面抗原细胞表面单克隆抗体细胞大白鼠家鼠属

Membrane lipid Replacement: Clinical Studies Using a Natural Medicine Approach to Restoring Membrane Function and Improving Health

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2016年第2期7卷 133-143页

作者： garth l. nicolson Department of Molecular Pathology The Institute for Molecular Medicine Huntington Beach CA USA

Functional oral supplements containing cell membrane glycerolphospholipids and antioxidants have been used to safely replace damaged membrane lipids that accumulate during aging and in various clinical conditions. This approach differs from other dietary and intravenous interventions in the composition of phospholipids and the presence of fructooligosaccharides that protect the phospholipids against oxidation and bile and enzymatic damage. Various chronic clinical conditions are characterized by membrane phospholipid oxidative damage, resulting in loss of cellular function. Recent clinical trials have shown the benefits of Membrane lipid Replacement in replenishing damaged membrane lipids and restoring mitochondrial function, resulting in reductions in fatigue in aged subjects and patients with a variety of clinical diagnoses. Recent in vitro experiments with nonphysiological concentrations of phospholipids did not result in enhancement of mitochondrial electron transport enzyme activities. This can be explained by the use of the wrong phospholipid fatty acids, over-dilution of membrane constituents and mitochondrial swelling. A similar phenomenon was seen when human sperm were incubated in vitro with high concentrations of glycerolphospholipids and their motility was assessed. Only lower, more physiological concentrations of glycerolphospholipids stimulated sperm motility. Additional studies are needed to determine the functional effects of Membrane lipid Replacement on other cellular membranes, such as the plasma membrane and other intracellular membranes of various cells and tissues.

关键词： Membrane Phospholipids lipid Oxidation Mitochondrial Function Fatigue Clinical Trials Membrane lipid Replacement

Pathogenic Mycoplasma Infections in Chronic Illnesses: General Considerations in Selecting Conventional and Integrative Treatments

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2019年第10期10卷 477-522页

作者： garth l. nicolson Department of Molecular Pathology The Institute for Molecular Medicine Huntington Beach California USA

The presence of pathogenic mycoplasmas in various chronic illnesses and their successful suppression using conventional and integrative medicine approaches are reviewed. Evidence gathered over the last three decades has demonstrated the presence of pathogenic mycoplasma species in the blood, body fluids and tissues from patients with a variety of chronic clinical conditions: atypical pneumonia, asthma and other respiratory conditions;oral cavity infections;urogenital conditions;neurodegenerative and neurobehavioral diseases;autoimmune diseases;immunosuppressive diseases;inflammatory diseases;and illnesses and syndromes of unknown origin, such as fatiguing illnesses. Only recently have these small intracellular bacteria received attention as possible causative agents, cofactors or opportunistic infections or co-infections in these and other conditions. Their clinical management is often inadequate, primarily because of missed diagnosis, under- and inadequate treatment and the presence of persister or dormant microorganisms due to biofilm, resistence and other mechanisms. Pathogenic Mycoplasma species infections have been suppressed slowly by anti-microbial and integrative treatments, resulting in gradual reductions in morbidity, but not in every patient. Even if mycoplasmas are not a cause or an initial trigger for many chronic illnesses, they appear to play important roles in the inception, progression, morbidity and relapse of chronic illnesses in rather large patient subsets. Ignoring such infections can result in failure to achieve eventual patient recovery, even with application of potentially curative treatments.

关键词： Chronic Diseases Infections Antibiotics Herbel Therapy Immune Enhancement Membrane lipid Replacement Mycoplasma Natural Supplements Integrative Medicine

COVID-19 Coronavirus: Is Infection along with <i>Mycoplasma</i>or Other Bacteria linked to Progression to a lethal Outcome?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2020年第5期11卷 282-302页

作者： garth l. nicolson Gonzalo Ferreira de Mattos Department of Molecular Pathology The Institute for Molecular Medicine Huntington Beach USA laboratory of Ion Channels Biological Membranes and Cell Signaling Department of Biophysics Facultad de Medicina Universidad de la República Montevideo Uruguay

Most patients with COVID-19 disease caused by the SARS-CoV-2 virus recover from this infection, but a significant fraction progress to a fatal outcome. As with some other RNA viruses, co-infection or activation of latent bacterial infections along with pre-existing health conditions in COVID-19 disease may be important in determining a fatal disease course. Mycoplasma spp. (M. pneumonaie, M. fermentans, etc.) have been routinely found as co-infections in a wide number of clinical conditions, and in some cases this has progressed to a fatal disease. Although preliminary, Mycoplasma pneumoniae has been identified in COVID-19 disease, and the severity of some signs and symptoms in progressive COVID-19 patients could be due, in part, to Mycoplasma or other bacterial infections. Moreover, the presence of pathogenic Mycoplasma species or other pathogenic bacteria in COVID-19 disease may confer a perfect storm of cytokine and hemodynamic dysfunction, autoimmune activation, mitochondrial dysfunction and other complications that together cannot be easily corrected in patients with pre-existing health conditions. The positive responses of only some COVID-19 patients to antibiotic and anti-malaria therapy could have been the result of suppression of Mycoplasma species and other bacterial co-infections in subsets of patients. Thus it may be useful to use molecular tests to determine the presence of pathogenic Mycoplasma species and other pathogenic bacteria that are commonly found in atypical pneumonia in all hospitalized COVID-19 patients, and when positive results are obtained, these patients should treated accordingly in order to improve clinical responses and patient outcomes.

关键词： Pathogenic Mycoplasma SARS-CoV-2 Virus COVID-19 Disease Acute Respiratory Distress Syndrome Co-Infection Pneumonia lethal Infection Mitochondria Cytokines Anti-Microbial Therapy Antibiotics Anti-Malarial Therapy Virus Bacteria

lipid Replacement Therapy with a Glycophospholipid Formulation with NADH and CoQ10 Significantly Reduces Fatigue in Intractable Chronic Fatiguing Illnesses and Chronic lyme Disease Patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2012年第3期3卷 163-170页

作者： garth l. nicolson Robert Settineri Rita Ellithorpe Department of Molecular Pathology The Institute for Molecular Medicine Huntington Beach USA Sierra Research Irvine USA Tustin longevity Center Tustin USA

Objectives: A preliminary open label study was initiated to determine if a combination oral supplement containing a mixture of phosphoglycolipids, coenzyme Q10 and microencapsulated NADH could affect fatigue levels in long-term patients with intractable fatigue. Fatigue was determined by the validated Piper Fatigue Scale before, during and after the trial. Participants included 58 patients (30 females and 28 males) with chronic fatigue syndrome/myalgic encephalomyelitis, chronic lyme disease or other fatiguing illnesses, such as fibromyalgia syndrome or Gulf War illness. These patients had been symptomatic for an average of 17.1 ± 0.6 years, had been seen by many physicians (15.2 ± 0.7) and had used many other supplements and drugs (35.4 ± 2.7) without apparent reductions in their fatigue. Results: Participants in the study responded to the combination test supplement, showing a 30.7% reduction in overall fatigue within 60 days (P2 = 0.960). The data also suggested that further reductions were likely if the participants had continued the supplement beyond the 8-week trial. Males responded slightly better to the combination supplement than females, and the patients with the most severe forms of fatigue responded slightly better than those with milder fatigue, independent of their diagnosis. Conclusions: The combination supplement was a safe and effective method to significantly reduce fatigue in long-term patients with intractable chronic fatigue.

关键词： Fatigue Chronic Fatigue Syndrome lyme Disease CoQ10 NADH Phospholipids

Treatment of Peripheral Neuropathy: Combination Therapy Using lED light, Extracorporeal Shockwave Therapy, Platelet Rich Plasma, and an Oral Dietary Supplement

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2023年第5期14卷 250-259页

作者： Alex Spinoso Robert Settineri Christine Mclaren garth l. nicolson Elite Medical Corona CA USA Sierra Productions Research Irvine California USA Department of Medicine University of California Irvine Irvine CA USA Institute for Molecular Medicine Huntington Beach CA USA

Objectives: Peripheral neuropathy (PN) is a significant contributor to disability in the elderly. It is also one of the most prevalent complications of type 2 diabetes, prediabetes and metabolic syndrome. PN is commonly associated with pain, numbness, tingling, burning, and cramping in the feet and legs. Current treatment options are limited to controlling pain, seizures and use of antidepressant medications. These treatments have undesirable side effects and don’t stop PN progression. Here we utilized a combination of individual-specific modalities to improve local circulation and relieve PN symptoms. Methods: We conducted an open-label, multicenter pilot trial with 34 subjects (19 males and 15 females ranging from 40 - 85 years of age). All of the participants were diagnosed with peripheral neuropathy and had bilateral symptoms in their feet, and many reported the same symptoms (pain, numbness, tingling, burning, and cramping) in their lower legs. The duration of symptoms ranged from four months to over six years. On Day 0, subjects were given a 90-day supply of the oral supplement with dosing instructions and a lED light therapy device. They also received three platelet-rich plasma (PRP) injections in their lower extremities. Subjects also received an extracorporeal shockwave therapy (ESWT) treatment for each foot and subsequently twice per week for the first six weeks, then once weekly for the duration of the study. Subjects filled out the Brief Pain Index (BPI) at weekly intervals. On Day 90, subjects completed the Patient Global Impression of Change (PGIC) survey. Results: There were significant responses to pain, as evidenced by BPI scores at weeks 8, 9, 10 and 11 (p = 0.02, 0.01, 0.02, and 0.003, respectively). Analysis of the final day PGIC survey showed a favorable outcome for 73% of participants (p = 0.003), with the majority reporting Very Much Improved. Conclusions: By utilizing a multi-modality treatment protocol that includes PRP, lED light therapy, E

关键词： Peripheral Neuropathy lED light Therapy Device Extracorporeal Shockwave Therapy PRP Injections Oral Supplement Multi-Modality Treatment Pain

Reduction of Pain, Fatigue, Gastrointestinal and Other Symptoms and Improvement in Quality of life Indicators in Fibromyalgia Patients with Membrane lipid Replacement Glycerolphospholipids and Controlled-Release Caffeine

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical Medicine 2018年第7期9卷 600-619页

作者： garth l. nicolson Robert Settineri Gonzalo Ferreira Paul Breeding Department of Molecular Pathology The Institute for Molecular Medicine Huntington Beach CA USA Sierra Research Irvine CA USA Department of Biophysics Facultad de Medicina Universidad de la Republica Ion Channels Laboratory Montevideo Uruguay Health First Pearland TX USA

Objectives: A preliminary, open label study was initiated to determine if oral wafers containing a combination of membrane glycerolphospholipids and controlled-release caffeine could reduce self-reported pain, fatigue, and gastrointestinal symptoms and improve quality of life (QOl) indicators in fibromyalgia patients. Methods: Pain, fatigue and other symptoms were determined using validated, patient survey forms completed over an 8-day test period and compared to baseline values. Participants included 21 patients (15 females and 6 males) of average age of 48.5 ± 9.8 years with a diagnosis of fibromyalgia. These patients consumed four daily chewable wafers containing glycerolphospholipids (4.8 g) and one controlled-released caffeine (184 mg) wafer that maintained caffeine levels at approximately one cup of coffee for over 8 h. Results: Participants in the study responded to the combination test supplement within days. By the end of the study there were significant overall improvements (36.1%, p p p p p Conclusions: The combination membrane lipid replacement glycerolphospholipid supplement with controlled-release caffeine was safe and effective and significantly reduced pain, fatigue and gastrointestinal symptoms as well as improved QOl indicators in fibromyalgia patients.

关键词： Pain Fatigue Gastrointestinal Symptoms Quality of life Phospholipids Caffeine

Mesenchymal stem cell-mediated cancer therapy: A dualtargeted strategy of personalized medicine

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Stem Cells 2011年第11期3卷 96-103页

作者： garth l Warnock Department of Surgery Uni-versity of British Columbia Vancouver BC V5Z 1L8 Canada

Cancer remains one of the leading causes of mortal-ity and morbidity throughout the world. To a signifi-cant extent, current conventional cancer therapies are symptomatic and passive in nature. The major obstacle to the development of effective cancer therapy is be-lieved to be the absence of suffi cient specifi city. Since the discovery of the tumor-oriented homing capacity of mesenchymal stem cells (MSCs), the application of specific anticancer gene-engineered MSCs has held great potential for cancer therapies. The dual-targeted strategy is based on MSCs’ capacity of tumor-directed migration and incorporation and in situ expression of tumor-specifi c anticancer genes. With the aim of trans-lating bench work into meaningful clinical applications, we describe the tumor tropism of MSCs and their use as therapeutic vehicles, the dual-targeted anticancer potential of engineered MSCs and a putative personal-ized strategy with anticancer gene-engineered MSCs.

关键词： Mesenchymal stem cells Gene therapy Cancer therapy Cytotherapy